"idoctor"

Publication year: 2009<br><b>Source:</b> The American Journal of Cardiology, In Press, Corrected Proof, Available online 26 September 2009<br>Hien-Tu, Nguyen-Thanh , Bruno S., Benzaquen<br><br>Traditional coronary risk assessment is based on major cardiovascular risk factors using the Framingham risk score. Carotid intima-media thickness (CIMT) measured by ultrasonography is a noninvasive test used to assess for the presence of coronary atherosclerosis. CIMT has been shown to be an independent predictor of future cardiovascular events and is used in research trials as a surrogate for the presence as well as regression of coronary artery disease. The objectives of this report are to review the published reports on CIMT and to help establish the role of CIMT as a screening tool for coronary artery disease in sele

Similar Posts:

• The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA).
• Adherence to 2005 Dietary Guidelines for Americans is associated with a reduced progression of coronary artery atherosclerosis in women with established coronary artery disease.
• Usefulness of Carotid Intima-Media Thickness in Patients With Diabetes Mellitus as a Predictor of Coronary Artery Disease
• Micronutrient concentrations and subclinical atherosclerosis in adults with HIV.
• Age-Modification of Lipoprotein, Lipid, and Lipoprotein Ratio-Associated Risk for Coronary Artery Calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA])
• Effect of Intensive Lifestyle Changes on Endothelial Function and on Inflammatory Markers of Atherosclerosis
• Usefulness of Breast Arterial Calcium Detected on Mammography for Predicting Coronary Artery Disease or Cardiovascular Events in Women With Angina Pectoris and/or Positive Stress Tests
• Cholesteryl Ester Transfer Protein, Coronary Calcium, and Intima-Media Thickness of the Carotid Artery in Middle-Age Japanese Men
• Low High-Density Lipoprotein Cholesterol and Increased Cardiovascular Disease Risk: An Analysis of Statin Clinical Trials
• Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?

Share/Save

This entry was posted on Tuesday, September 29th, 2009 at 3:14 am and is filed under Health news. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.